Jump to content


  • Content Count

  • Joined

  • Last visited

  • Days Won

  • Country

    United Arab Emirates

srichar3 last won the day on January 15

srichar3 had the most liked content!

Profile Information

  • Gender
  • Occupation
    Blood Bank Manager

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. I carnt really see any other explanation for it and would be interested to hear from any other Ortho users who have this latest CAP. Yes the backgroup was clear on Diamed/Bio-rad and they too had a c Poitive A cell, I tried the same cells on Ortho and it was Poitive, then switched to a screened A cell that was c Neg and it was clear. I didnt panel the antibody but going off the screening cell result it can only be anti-c.
  2. It could be that the cells are coated but not sufficient to get a positive result. However when you perform the eluate on a large enough number of RBC'c the amount of IgG removed from these red cell's is then enough to coat and cause a positive reaction on the screening cells. Also the cells from the DAT will be heterozygous cells, hence you will get a stronger reaction from screening cells that are homozygous if sufficient antibody is eluted to coat them.
  3. JAT-C Got to the bottom of it with one of them, it was Anti-c antibody positive and was cold reactive with the A cells. Switched for some c- cells and now clear.
  4. How common is DVI? Have done a google search but carnt find much information. Any sites that actually dual screen neonates or adults with both DVI+ and DVI- D clones? If so how often do you identify one if ever? Thanks
  5. I'm currently in the process of validating a new analyser, the Ortho Vision. I have validated this particular analyser before in the UK back in 2015. Now I'm working for a lab that is currently going through the process of AABB accreditation so I want to make sure I have covered all their requirements as this is my first experience with AABB. So far I have done comparisons, reagent on-board stability, carry over for antibodies (tested up to the Ortho claimed limit of 1:1024 titre), I also intend to do repeatability, running the same samples 5 times in a row to make sure the grading and interpretation is correct, the pathologist wanted 20 but I pointed out there is no way we will get 20 runs out of a transfusion sample. This is as much as I did in the UK and we had ISO shortly after and they were very satisfied with what we had done. As I have no experience with AABB I would like to hear from anyone who has gone through this process and has AABB experience. Is there anything I'm missing? Thanks
  6. I'm in the process of validating our new Ortho vision Analyzer and have just run our latest CAP specimens however I'm getting false positives on the back groups. Does anyone else use this analyser? are there any know issues with CAP specimens? Thanks
  7. Currently our lab ignores +/-, 0.5, or weak positive results (depending what your technology classes them as) on titres, hence we only report the titre as the value that gives a minimum 1+ reaction. Is this usual practice? recently we are getting alot of +/- Anti-D's that are only giving very weak reactions in IAT but confirmed in the Enzyme, hence when titrated they dont meet the criteria to be classed as a even a "neat" so we report them as too weak to titre. Just wanted to check if this is standard practice as in my previous experience all titres were sent to reference lab and I never saw any report that wasn't at least a "neat" Thanks
  8. In the UK the MHRA who are the UK equivalent of the FDA licence all blood facilities and hospital blood banks. One area they are very big on is change control. I just wondered how much the AABB focus on this area as at the moment our laboratory does not have a specific documented process for change control. Thanks
  9. Yes and this is what I've gone with, think its the easiest all round and the way I'm used to working. Thanks
  10. Annual Management Review meeting. Although AABB just refer to it as scheduled management review in the standards, I've only ever know them to be done annually unless AABB expect more frequent?
  11. I wish, if I was I could make it 100 times better than what we have, its been designed by people who have clearly no concept of blood bank.
  12. If AABB accredited is there a minimum expectation from the AABB as to the Blood Bank topics discussed at the AMR? We have our AMR coming up shortly and are also starting our accreditation process with the AABB. I want to ensure we have covered all bases. Thanks
  13. I am working on implementing a new blood bank system which has a very poor Crossmatch/Blood issue process, I'm looking for some examples to give to our IT department as to how other systems manage this process because I think they think I'm wanting something that is top level functionality when I see it as a basic requirement. Please can you give a brief outline of your LIS Crossmatch/Issue processes for me. Thanks
  14. When you say you have them all listed, do you mean you have them listed as individual product codes, I'e the product description but under one main category heading? or you have a category for each class or product. For example a category for packed RBC's with all the possible product's within this description, then a separate category for apheresis RBC's with all the possible products listed under this category, a seperate category for irradiated RBC's with all the possible products listed under this, then a different category for apeheresis irradiated RBC's and so on so forth, rather than just calling them all PRBC's then listing the individual product descriptions under the one category for PRBC's. If you say the Dr's only see the 4 main category's this implies all PRBC's individual codes are listed together under the one main PRBC category? This is the way I'm used to it been. Thanks
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.